The stock of Amneal Pharmaceuticals Inc (AMRX) has gone up by 1.77% for the week, with a -4.62% drop in the past month and a -6.93% drop in the past quarter. The volatility ratio for the week is 3.20%, and the volatility levels for the past 30 days are 3.30% for AMRX. The simple moving average for the last 20 days is 2.43% for AMRX’s stock, with a simple moving average of 7.43% for the last 200 days.
Is It Worth Investing in Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Right Now?
The 36-month beta value for AMRX is at 1.10. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AMRX is 126.70M, and currently, shorts hold a 2.79% of that float. The average trading volume for AMRX on January 10, 2025 was 1.05M shares.
AMRX) stock’s latest price update
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) has experienced a rise in its stock price by 2.41 compared to its previous closing price of 7.87. However, the company has seen a gain of 1.77% in its stock price over the last five trading days. zacks.com reported 2025-01-08 that Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Analysts’ Opinion of AMRX
Many brokerage firms have already submitted their reports for AMRX stocks, with JP Morgan repeating the rating for AMRX by listing it as a “Neutral.” The predicted price for AMRX in the upcoming period, according to JP Morgan is $9 based on the research report published on September 06, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see AMRX reach a price target of $5. The rating they have provided for AMRX stocks is “Sector Perform” according to the report published on April 07th, 2021.
Goldman gave a rating of “Buy” to AMRX, setting the target price at $6.50 in the report published on March 08th of the previous year.
AMRX Trading at -2.58% from the 50-Day Moving Average
After a stumble in the market that brought AMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.93% of loss for the given period.
Volatility was left at 3.30%, however, over the last 30 days, the volatility rate increased by 3.20%, as shares sank -0.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.05% lower at present.
During the last 5 trading sessions, AMRX rose by +1.77%, which changed the moving average for the period of 200-days by +32.78% in comparison to the 20-day moving average, which settled at $7.87. In addition, Amneal Pharmaceuticals Inc saw 1.77% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMRX starting from Patel Gautam, who sale 17,410 shares at the price of $8.01 back on Jan 02 ’25. After this action, Patel Gautam now owns 2,031,476 shares of Amneal Pharmaceuticals Inc, valued at $139,454 using the latest closing price.
Gautam J Patel, the Director of Amneal Pharmaceuticals Inc, proposed sale 320,000 shares at $8.00 during a trade that took place back on Jan 02 ’25, which means that Gautam J Patel is holding shares at $2,560,000 based on the most recent closing price.
Stock Fundamentals for AMRX
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.35 for the gross margin
The net margin for Amneal Pharmaceuticals Inc stands at -0.07. The total capital return value is set at 0.08. Equity return is now at value -155.38, with -5.16 for asset returns.
Based on Amneal Pharmaceuticals Inc (AMRX), the company’s capital structure generated 1.04 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at -27.12. The interest coverage ratio of the stock is 0.73.
Currently, EBITDA for the company is 399.76 million with net debt to EBITDA at 5.32. When we switch over and look at the enterprise to sales, we see a ratio of 2.35. The receivables turnover for the company is 3.58for trailing twelve months and the total asset turnover is 0.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.38.
Conclusion
In conclusion, Amneal Pharmaceuticals Inc (AMRX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
